Tag : ENZALUTAMIDE

  • CONFERENCE UPDATE
    Enzalutamide + Ra223 shows rPFS benefits in asymptomatic or mildly symptomatic patients with bone-metastatic mCRPC: Results from the PEACE-3 trial

    Abiraterone and enzalutamide (ENZ) are established first-line treatments for patients with metastatic castration-resistant prostate cancer (mCRPC) who progress on androgen deprivation therapy (ADT). Radium-223 dichloride (Ra223), an alpha particle-emitting calcium mimetic, selectively targets bone metastases by inducing double-strand deoxyribonucleic acid (DNA) breaks. The ERA-223 trial, which tested the combination of abiraterone with Ra223, found no improvement in symptomatic skeletal event-free survival or overall survival (OS). No combination so far has been proven in both radiological progression-free survival (rPFS) and OS as a first-line mCRPC treatment. In response, the PEACE-3 trial, a collaboration of EORTC, CTI, CUOG, LACOG, and UNICANCER, was launched to assess whether combining ENZ with Ra223 (ENZ + Ra223) could enhance cancer progression outcomes compared to ENZ alone in mCRPC patients.